Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Celecoxib NDA receives priority review designation for FAP

Aug. 31, 1999

Searle pays milestone to Epimmune for anticancer candidate

Aug. 31, 1999

LB-42908 inhibits protein farnesyltransferase in vitro, in vivo

Aug. 30, 1999

Preclinical studies of abetafen show potential for treatment of prostate disease

Aug. 30, 1999

Cytotoxic macrolide compounds HA-1 and TH-2 obtained from marine sources

Aug. 30, 1999

NaPro BioTherapeutics focuses on new anticancer programs

Aug. 30, 1999

NuOncology Labs awarded second U.S. patent

Aug. 30, 1999

Evacet/Taxol combination enters advanced breast cancer trials

Aug. 30, 1999

Cell Pathways seeks approval of Aptosyn in the U.S.

Aug. 27, 1999

Temodal approved in E.U. for treatment of recurrent anaplastic astrocytoma

Aug. 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...